To provide optimal patient care, hematologists, oncologists, nurses, pharmacists, and other health care professionals must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with DLBCL and the clinical utility of targeted agents, such as BTKis, that could significantly impact patient outcomes. Precision medicine approaches represent the future of DLBCL treatment, and clinicians must be knowledgeable regarding the methods and clinical relevance of modern genetic testing. They must be able to individualize therapy based on patient characteristics in addition to clinical factors. Moreover, they must be able to implement and apply genetic methods not only for prognostication but also to guide therapy selection and optimization, leading to improved outcomes for patients with DLBCL.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedFeb 11, 2026
-
Last day to claim creditFeb 12, 2027 4 months left
-
Physicians’ Education Resource Module 4: Diffuse Large B-Cell Lymphoma (DLBCL)
-
Medscape, LLC Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case Based Discussion
-
CancerNet +1 Changing Landscape of DLBCL Treatment: ADCs, Bispecific Antibodies, CAR T Therapies, and Combinations
-
Plexus Communications +1 Blueprints for Better Outcomes: BTK Inhibitors for Specific DLBCL Biological Subtypes
-
Plexus Communications +1 Advancing Metastatic NSCLC: The Role of HER2- and TROP2-Targeted Antibody-Drug Conjugates
-
Plexus Communications +1 Advancing Frontline Therapy in Mantle Cell Lymphoma: The Evolving Role of BTK Inhibitors
